| Budget Amount *help |
¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2013: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2012: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2011: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
|
|---|
| Research Abstract |
Pediatric solid tumors are one of the significant causes of death among children, and thus, development for new therapeutic strategy for intractable pediatric solid tumors is a global problem. To identify molecular targets of pediatric solid tumors and regulators of cancer stem cells, we performed target sequencing and exome sequencing using next generation sequencing technology. Target sequencing of 80 polycomb protein genes in 96 of neuroblastomas revealed that ASH1L mutations occurred in about 10% of cases. Thus, this gene is one of the candidate target for cancer stem cells regulators of neuroblastoma. In exome analysis of 16 cases of rhabdomyosarcoma (RMS), we identified FGFR4 pathway mutations in about 30% of all cases, and this pathway mutation was more frequently detected in embryonal subtype. Therefore, the inhibitor of FGFR4 pathway could be one of the promising therapeutic molecule for embryonal RMS.
|
